FHTX Foghorn Therapeutics Inc.

NASDAQ
$1.78

Foghorn Therapeutics Inc. (FHTX) is expected to report earnings on February 8, 2027, before the market open. The consensus earnings estimate is a loss of $0.29 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.4% since its last earnings release on November 9, 2026.

Foghorn Therapeutics Beat Consensus Estimates
Monday, November 9, 2026 · 7:22 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 8
Monday · 7:00 AM ET
Earnings Whisper
-
vs ($0.29)
Rev est $4.5M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $1.93

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.